FOXO4-DRI
FOXO4-p53 interfering peptide studied as a targeted senolytic in cellular senescence research.
Testing & quality
Every batch is supplier-tested for identity and purity and randomly verified by independent third-party HPLC and mass spectrometry.
Compound classification
Synthetic D-retro-inverso (DRI) peptide derived from the FOXO4 transcription factor.
Mechanism studied in the literature
Designed to disrupt the FOXO4–p53 interaction in senescent cells, releasing p53 to the nucleus and inducing selective apoptosis of senescent cells in preclinical models without affecting healthy proliferating cells.
Research areas
- Cellular senescence and senolytic screening
- FOXO4 / p53 protein–protein interaction biology
- Tissue homeostasis and SASP (senescence-associated secretory phenotype) studies
- Geroscience and age-related disease models
Storage
Lyophilized: -20°C, protected from light, for long-term stability. Reconstituted: 2-8°C, use within 28 days under sterile laboratory conditions. Avoid freeze-thaw cycles.
Reconstitution (laboratory)
Reconstitute with bacteriostatic or sterile water for injection (USP grade). Swirl gently to dissolve.
Notes
Sold strictly as a reference research compound for in-vitro laboratory study. Independently HPLC/MS verified at 99%+ purity.
Related research peptides
Epithalon
Tetrapeptide studied for telomerase activation, circadian regulation, and longevity research.
NAD+
Coenzyme studied for mitochondrial function, DNA repair, and cellular energy.
Glutathione
Master antioxidant studied for oxidative stress reduction and detoxification research.
SS-31
Mitochondria-targeted peptide researched for cardiolipin protection and cellular bioenergetics.